Corixa expects Bexxar advisory cmte. review
Executive Summary
Corixa expects to present Bexxar (tositumomab) to FDA's Oncologic Drug Advisory Committee before the end of the year. The committee has cancelled its Sept. 23 meeting date, but is tentatively scheduled to reconvene Dec. 17 and 18. Corixa requested the review in its appeal of a March 12 "complete review" letter for the non-Hodgkin's lymphoma therapy (1"The Pink Sheet" July 1, In Brief)...
You may also be interested in...
GSK/Corixa Bexxar NDA
Corixa/GlaxoSmithKline's Bexxar (tositumomab) could receive review for treatment of low-grade or transformed low-grade non-Hodgkin's lymphoma by FDA's Oncologic Drugs Advisory Committee at the tentatively scheduled Sept. 23-24 meeting. Corixa requested committee review of the drug in its appeal of a March 12 "complete review" letter (1"The Pink Sheet" May 20, In Brief)...
European CHMP Opinions and MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
UK’s NICE Backs Two Microsphere Products For Liver Cancer But Says No To Another
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: